A Study to Examine the Effect of Daridorexant on the Way the Body Absorbs, Distributes, and Gets Rid of Dabigatran and Rosuvastatin in Healthy Male Subjects

Phase 1 Completed 24 enrolled Idorsia Pharmaceuticals Ltd.

NaSequentialOpen-labelOther

Summary

A study to examine the effect of daridorexant on the way the body absorbs, distributes, and gets rid of dabigatran and rosuvastatin in healthy male subjects

Timeline

Start: 2022-09-03
Primary completion: 2022-09-17
Completion: 2022-09-17

Publications

Anliker-Ort M, Dingemanse J, Janu L, Kaufmann P. Effect of Daridorexant on the Pharmacokinetics of P-Glycoprotein Substrate Dabigatran Etexilate and Breast Cancer Resistance Protein Substrate Rosuvastatin in Healthy Subjects. Clin Drug Investig. 2023 Nov;43(11):827-837. doi: 10.1007/s40261-023-01310-6. Epub 2023 Oct 19.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Dabigatran etexilate	Unknown	75 mg	Oral
Subject	Daridorexant	Small molecule	50 mg	—
Subject	Rosuvastatin	Small molecule	10 mg	Oral

Indications

No indication recorded.